Antibodies play a central role in prophylaxis against many infectious agents. While neutralization is a primary function of antibodies, the Fc- and complement-dependent activities of these multifunctional proteins may also be critical in their ability to provide protection against most viruses. Protection against viral pathogens in vivo is complex, and while virus neutralization—the ability of antibody to inactivate virus infectivity, often measured in vitro—is important, it is often only a partial contributor in protection. The rapid fluorescent focus inhibition test (RFFIT) remains the “gold standard” assay to measure rabies virus–neutralizing antibodies. In addition to neutralization, the rabies-specific antigen-binding activity of antibodies may be measured through enzyme-linked immunosorbent assays (ELISAs), as well as other available methods. For any disease, in selecting the appropriate assay(s) to use to assess antibody titers, assay validation and how they are interpreted are important considerations—but for a fatal disease like rabies, they are of paramount importance. The innate limitations of a one-dimensional laboratory test for rabies antibody measurement, as well as the validation of the method of choice, must be carefully considered in the selection of an assay method and for the interpretation of results that might be construed as a surrogate of protection.
References
[1]
Smith JS, Yager PA, Baer GM (1973) A rapid reproducible test for determining rabies neutralizing antibody. Bull World Health Organ 48: 535–541.
[2]
Aubert MF (1992) Practical significance of rabies antibodies in cats and dogs. Rev Sci Tech 11: 735–760.
[3]
Hooper DC, Morimoto K, Bette M, Weihe E, Koprowski H, Dietzschold B (1998) Collaboration of antibody and inflammation in clearance of rabies virus from the central nervous system. J Virol 72: 3711–3719.
[4]
Dietzschold B (1993) Antibody-mediated clearance of viruses from the mammalian central nervous system. Trends Microbiol 1: 63–66. doi: 10.1016/0966-842X(93)90035-P
[5]
Tordo N (1996) Characteristics and molecular biology of the rabies virus. In: Meslin FX, Kaplan MM, Koprowski H, editors. Laboratory Techniques in Rabies. Geneva: World Health Organization. pp. 28–51.
[6]
Fu ZF, Dietzschold B, Schumacher CL, Wunner WH, Ertl HC, Koprowski H (1991) Rabies virus nucleoprotein expressed in and purified from insect cells is efficacious as a vaccine. Proc Natl Acad Sci U S A 88: 2001–2005. doi: 10.1073/pnas.88.5.2001
[7]
Irie T, Kawai A (2002) Studies on the different conditions for rabies virus neutralization by monoclonal antibodies #1-46-12 and #7-1-9. J Gen Virol 83: 3045–3053.
[8]
Flamand A, Raux H, Gaudin Y, Ruigrok RW (1993) Mechanisms of rabies virus neutralization. Virology 194: 302–313. doi: 10.1006/viro.1993.1261
[9]
Hessell AJ, Hangartner L, Hunter M, Havenith CE, Beurskens FJ, Bakker JM, Lanigan CM, Landucci G, Forthal DN, Parren PW, Marx PA, Burton DR (2007) Fc receptor but not complement binding is important in antibody protection against HIV. Nature 449: 101–104. doi: 10.1038/nature06106
[10]
Hanlon CA, Niezgoda M, Rupprecht CE (2002) Postexposure prophylaxis for prevention of rabies in dogs. Am J Vet Res 63: 1096–1100. doi: 10.2460/ajvr.2002.63.1096
[11]
Beran J, Honegr K, Banzhoff A, Malerczyk C (2006) How far can the antigen content of tissue culture rabies vaccine be reduced safely? Vaccine 24: 2223–2224. doi: 10.1016/j.vaccine.2005.12.003
[12]
Strady C, Jaussaud R, Beguinot I, Lienard M, Strady A (2000) Predictive factors for the neutralizing antibody response following pre-exposure rabies immunization: validation of a new booster dose strategy. Vaccine 18: 2661–2667. doi: 10.1016/S0264-410X(00)00054-2
[13]
Ovsyannikova IG, Jacobson RM, Ryan JE, Vierkant RA, Pankratz VS, Jacobsen SJ, Poland GA (2005) HLA class II alleles and measles virus-specific cytokine immune response following two doses of measles vaccine. Immunogenetics 56: 798–807. doi: 10.1007/s00251-004-0756-0
[14]
Kuwert EK, Barsenbach J, Werner J, Marcus I, Scheiermann N, et al. (1981) Early/High and Late/Low Responders among HDCS Vaccinees. In: Kuwert EK, Wiktor RJ, Koprowski H, editors. Cell Culture Rabies Vaccines and Their Protective Effect in Man. Geneva: International Green Cross. pp. 160–168.
[15]
Reading SA, Dimmock NJ (2007) Neutralization of animal virus infectivity by antibody. Arch Virol 152: 1047–1059. doi: 10.1007/s00705-006-0923-8
[16]
Jackson AC (2002) Pathogenesis. In: Jackson AC, Wunner WH, editors. Rabies. San Diego, CA: Academic Press. pp. 246–282.
[17]
Hotta K, Bazartseren B, Kaku Y, Noguchi A, Okutani A, Inoue S, Yamada A (2009) Effect of cellular cholesterol depletion on rabies virus infection. Virus Res 139: 85–90. doi: 10.1016/j.virusres.2008.10.009
[18]
Bigler WJ, Hoff GL, Smith JS, McLean RG, Trevino HA, Ingwersen J (1983) Persistence of rabies antibody in free-ranging raccoons. J Infect Dis 148: 610. doi: 10.1093/infdis/148.3.610
[19]
Hanlon CA, Niezgoda M, Rupprecht CE (2007) Rabies in terrestrial animals. In: Jackson AC, Wunner WH, editors. Rabies. London: Academic Press. pp. 201–246.
[20]
Elmgren LD, Wandeler AI (1996) Competitive ELISA for the detection of rabies virus neutralizing antibodies. In: Meslin FX, Kaplan MM, Koprowski H, editors. Laboratory techniques in rabies. Geneva, Switzerland: World Health Organization. pp. 200–208.
[21]
Nadin-Davis SA, Sheen M, Abdel-Malik M, Elmgren L, Armstrong J, Wandeler AI (2000) A panel of monoclonal antibodies targeting the rabies virus phosphoprotein identifies a highly variable epitope of value for sensitive strain discrimination. J Clin Microbiol 38: 1397–1403.
[22]
Wright E, Temperton NJ, Marston DA, McElhinney LM, Fooks AR, Weiss RA (2008) Investigating antibody neutralization of lyssaviruses using lentiviral pseudotypes: a cross-species comparison. J Gen Virol 89: 2204–2213. doi: 10.1099/vir.0.2008/000349-0
[23]
Burton DR (2002) Antibodies, viruses and vaccines. Nat Rev Immunol 2: 706–713. doi: 10.1038/nri891
[24]
World Health Organization (1992) 824. World Health Organization expert committee on rabies: Eighth report.
[25]
Centers for Disease Control and Prevention (2008) Human Rabies Prevention --- United States, 2008. 57: 1–26.
[26]
Briggs DJ, Schweitzer K (2001) Importation of dogs and cats to rabies-free areas of the world. Vet Clin North Am Small Anim Pract 31: 573–83, viii.
[27]
Welch RJ, Anderson BL, Litwin CM (2009) An evaluation of two commercially available ELISAs and one in-house reference laboratory ELISA for the determination of human anti-rabies virus antibodies. J Med Microbiol 58: 806–810. doi: 10.1099/jmm.0.006064-0
[28]
Cliquet F, Aubert M, Sagne L (1998) Development of a fluorescent antibody virus neutralisation test (FAVN test) for the quantitation of rabies-neutralising antibody. J Immunol Methods 212: 79–87. doi: 10.1016/S0022-1759(97)00212-3
[29]
Grassi M, Wandeler AI, Peterhans E (1989) Enzyme-linked immunosorbent assay for determination of antibodies to the envelope glycoprotein of rabies virus. J Clin Microbiol 27: 899–902.
[30]
Marissen WE, Kramer RA, Rice A, Weldon WC, Niezgoda M, Faber M, Slootstra JW, Meloen RH, Clijsters-Van der HM, Visser TJ, Jongeneelen M, Thijsse S, Throsby M, de KJ, Rupprecht CE, Dietzschold B, Goudsmit J, Bakker AB (2005) Novel rabies virus-neutralizing epitope recognized by human monoclonal antibody: fine mapping and escape mutant analysis. J Virol 79: 4672–4678. doi: 10.1128/JVI.79.8.4672-4678.2005
[31]
Polonis VR, Brown BK, Rosa BA, Zolla-Pazner S, Dimitrov DS, Zhang MY, Barnett SW, Ruprecht RM, Scarlatti G, Fenyo EM, Montefiori DC, McCutchan FE, Michael NL (2008) Recent advances in the characterization of HIV-1 neutralization assays for standardized evaluation of the antibody response to infection and vaccination. Virology 375: 315–320. doi: 10.1016/j.virol.2008.02.007
[32]
Moore SM, Ricke TA, Davis RD, Briggs DJ (2005) The influence of homologous vs. heterologous challenge virus strains on the serological test results of rabies virus neutralizing assays. Biologicals 33: 269–276. doi: 10.1016/j.biologicals.2005.06.005
[33]
Fitzgerald EA, Baer GM, Cabasso VF, Vallancourt RF (1975) A collaborative study on the potency testing of antirabies globulin. J Biol Stand 3: 273–278. doi: 10.1016/0092-1157(75)90030-X
[34]
Fitzgerald EA, Rastogi SC (1985) A collaborative study to establish an International Standard Rabies immunoglobulin of human origin. J Biol Stand 13: 327–333. doi: 10.1016/S0092-1157(85)80047-0
[35]
Lyng J, Bentzon MW, Ferguson M, Fitzgerald EA (1992) Rabies vaccine standardization: International Collaborative Study for the Characterization of the fifth International Standard for Rabies Vaccine. Biologicals 20: 301–313.
[36]
Lyng J (1994) Calibration of a replacement preparation for the International Standard for Rabies Immunoglobulin. Biologicals 22: 249–255. doi: 10.1006/biol.1994.1036
